Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.

Also called NCT07659574

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 360 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07659574
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07659574. Randomized; triple masking; primary purpose treatment. Start 2026-09-07 (actual); primary completion 2027-09-24 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1)
Acronym
UNIGUIDE-1
Intervention (Drug)
UBT251 Injection 2.0 mg
Intervention (Drug)
UBT251 Injection 4.0 mg
Intervention (Drug)
UBT251 Injection 6.0 mg
Intervention (Drug)
UBT251 Injection Placebo 2.0 mg
Intervention (Drug)
UBT251 Injection Placebo 4.0 mg
Intervention (Drug)
UBT251 Injection Placebo 6.0 mg
Lead sponsor
The United Bio-Technology (Hengqin) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07659574
Content hash
6b8c141c27d72f3eda308395b802c051350d4fc2dba386fc97d771b97deae12d